Meridian Shares Fall 6.7% After DA Davidson Downgrade
Meridian shares fell 6.7% after DA Davidson downgraded the stock.
Related stories
Spyre Therapeutics Reports Q3 2026 Results and Positive SPY003 Trial Data
Spyre Therapeutics reported third-quarter 2026 financial results and announced positive topline induction data for SPY003 from Part A of its Phase 2 SKYLINE trial.
M impact | EQUITY | Nov 03, 2026, 09:14 PM UTC
Ardelyx reports third-quarter loss of $737,000
M impact | EQUITY | Nov 03, 2026, 09:14 PM UTC
Aquestive Therapeutics Reports Third-Quarter 2026 Financial Results and Business Update
M impact | EQUITY | Nov 03, 2026, 09:03 PM UTC
Ardelyx Reports Q3 2026 Financial Results
Ardelyx reported Q3 2026 total product revenue of $125.5 million, up 19% year over year. The supplied body is truncated after an IBSRELA reference.
M impact | EQUITY | Nov 03, 2026, 09:02 PM UTC
Amgen Reports Third-Quarter 2026 Financial Results
M impact | EQUITY | Nov 03, 2026, 09:02 PM UTC
Ardelyx Reports Third-Quarter Revenue of $127.7 Million
M impact | EQUITY | Nov 03, 2026, 09:01 PM UTC